Abstract
Endoproteolysis is a normal post-translational process in the eukaryotic cell that plays a role in protein evolution allowing protein catabolism and the generation of amino acids. Endoproteolytic cleavage regulates many crucial cellular processes including the activity of many proteins, their protein-protein interactions and the amplification of cell signals. Not surprisingly, disruption or alternation of endoproteolytic cleavage may be the root cause of many human diseases such as Alzheimer’s disease, Huntington’s disease and prion diseases. Most neurodegenerative diseases (ND) are caused by the build-up of misfolded proteins and the promotion of aggregation events. A common event that occurs in these ND is the alteration of endoproteolytic cleavage due to genetic mutations of the associated-proteases or target substrate. Endoproteolytic cleavage resulting in protein truncation has significant effects on the structure and function of a protein representing a common feature of ND. In this review, we will discuss the endoproteolytic cleavage events that lead to ND, namely Alzheimer’s disease, Huntington’s disease and prion diseases.
Keywords: Alzheimer’s disease, endoproteolytic cleavage, huntington’s disease, prion disease.
CNS & Neurological Disorders - Drug Targets
Title:The Role of Endoproteolytic Processing in Neurodegeneration
Volume: 15 Issue: 10
Author(s): Cornelia M. Wilson, Gohar Mushtaq, Mohammad A. Kamal and Faraj Terro
Affiliation:
Keywords: Alzheimer’s disease, endoproteolytic cleavage, huntington’s disease, prion disease.
Abstract: Endoproteolysis is a normal post-translational process in the eukaryotic cell that plays a role in protein evolution allowing protein catabolism and the generation of amino acids. Endoproteolytic cleavage regulates many crucial cellular processes including the activity of many proteins, their protein-protein interactions and the amplification of cell signals. Not surprisingly, disruption or alternation of endoproteolytic cleavage may be the root cause of many human diseases such as Alzheimer’s disease, Huntington’s disease and prion diseases. Most neurodegenerative diseases (ND) are caused by the build-up of misfolded proteins and the promotion of aggregation events. A common event that occurs in these ND is the alteration of endoproteolytic cleavage due to genetic mutations of the associated-proteases or target substrate. Endoproteolytic cleavage resulting in protein truncation has significant effects on the structure and function of a protein representing a common feature of ND. In this review, we will discuss the endoproteolytic cleavage events that lead to ND, namely Alzheimer’s disease, Huntington’s disease and prion diseases.
Export Options
About this article
Cite this article as:
Wilson M. Cornelia, Mushtaq Gohar, Kamal A. Mohammad and Terro Faraj, The Role of Endoproteolytic Processing in Neurodegeneration, CNS & Neurological Disorders - Drug Targets 2016; 15 (10) . https://dx.doi.org/10.2174/1871527315666160922163511
DOI https://dx.doi.org/10.2174/1871527315666160922163511 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuroinflammation and its Modulation by Flavonoids
Endocrine, Metabolic & Immune Disorders - Drug Targets A Knock-Down Cell-Based Study for the Functional Analysis of Chloride Intracellular Channel 1 (CLIC1): Integrated Proteomics and Microarray Study
Protein & Peptide Letters Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases
Current Medicinal Chemistry Modulation of Sirtuins: New Targets for Antiageing
Recent Patents on CNS Drug Discovery (Discontinued) Coordination of Ribosomal Protein and Ribosomal RNA Gene Expression in Response to TOR Signaling
Current Genomics Senescence of the Brain: Focus on Cognitive Kinases
Current Pharmaceutical Design Therapy Stratifications and Novel Approach in Pursuit of Aids Related Kaposi’s Sarcoma Management- A paradigm for Non Invasiveness
Current Drug Delivery In Vitro and In Vivo Transformations of Lutein
Mini-Reviews in Organic Chemistry A Biomarker Combining Imaging and Neuropsychological Assessment for Tracking Early Alzheimer's Disease in Clinical Trials
Current Alzheimer Research Editorial (Thematic Issue: From Old Cannabinoids to Emerging New Synthetic Derivatives with Potential Therapeutic Application in Neurological Disorders)
Recent Patents on CNS Drug Discovery (Discontinued) Quinolones and Fluoroquinolones to Treat Salmonella Typhimurium: A Review of Metabolism and Pharmacokinetics
Current Drug Metabolism IgE-Mediated Disorders: Current Therapeutics and New Strategies Involving Synthetic Peptides
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Bioactive Compounds Containing Benzoxadiazole, Benzothiadiazole, Benzotriazole
Current Bioactive Compounds Ginsenoside Rg1 Attenuates Oligomeric Aβ1-42-Induced Mitochondrial Dysfunction
Current Alzheimer Research Influence of ESR1 Variants on Clinical Characteristics and Fibromyalgia Syndrome in Turkish Women
Endocrine, Metabolic & Immune Disorders - Drug Targets The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies
Current Topics in Medicinal Chemistry Cysteine-, Methionine- and Seleno-Cysteine-Proline Chimeras: Synthesis and Their Use in Peptidomimetics Design
Current Bioactive Compounds Valproate and Neuroendocrine Changes in Relation to Women Treated for Epilepsy and Bipolar Disorder: A Review
Current Medicinal Chemistry Editorial [Hot Topic: Coming Back to Nature: Plants as a Vital Source of Pharmaceutically Important Metabolites (Guest Editor: Milen I. Georgiev)]
Current Medicinal Chemistry CXCR3, CXCR5, CXCR6, and CXCR7 in Diabetes
Current Drug Targets